Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

What are Viruses?

What are Viruses?

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Hepatic Portal System

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Hepatic Drug Excretion: Influencing Factors

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

Hepatic Drug Clearance: Role of Transporters

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

RNF213 isoform 2 restricts Zika virus through antiviral signaling and viral protein degradation.

iScience·2026

Same author

Editorial: Host factors in hepatitis B virus: mechanistic insights and implications for interferon therapy.

Frontiers in immunology·2026

Same author

NSP1 of Alongshan virus antagonizes type I interferon responses by promoting STUB1-mediated degradation of RIG-I.

Cell communication and signaling : CCS·2026

Same author

RapidArc Dynamic (RAD) multi-mechanical axis optimization achieves enhanced OAR sparing in cervical cancer: A dosimetric comparison study.

Journal of applied clinical medical physics·2026

Same author

NF-κB: master regulator of cellular responses in health and disease.

Immunity & inflammation·2026

Same author

Impacts of neutralizing antibody responses on SARS-CoV-2 evolution and its associated disease progression.

Immunity & inflammation·2026

Same journal

Mapping the multigenomic human system: structural asymmetry and interface gaps in host-exogenous biological interactions.

Frontiers in microbiology·2026

Same journal

Bacterial resistance across habitats: from German schools to the International Space Station.

Frontiers in microbiology·2026

Same journal

Correction: Unlocking plant growth-promoting traits of endophytic actinobacteria isolated from <i>Anacyclus pyrethrum</i>, an endemic medicinal plant of the Aguelmam azegza region, Morocco.

Frontiers in microbiology·2026

Same journal

Research progress on <i>Avibacterium paragallinarum</i> and related bacterial and viral diseases in poultry and their mixed infections.

Frontiers in microbiology·2026

Same journal

Development and validation of a quantitative method for the enumeration of <i>Salmonella enterica</i> serovar Infantis from environmental poultry feces based on most probable number approach followed by confirmatory qPCR.

Frontiers in microbiology·2026

Same journal

Multi-omics insights into the microbial and metabolic drivers of regional flavor diversity in Guizhou traditional fermented fish.

Frontiers in microbiology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 7, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

When Hepatitis B Virus Meets Interferons.

Guangyun Tan¹, Hongxiao Song¹, Fengchao Xu¹

¹Department of Immunology, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, China.

Frontiers in Microbiology

|August 4, 2018

Summary

This summary is machine-generated.

Interferon (IFN) combats chronic hepatitis B virus (HBV) infection by boosting immunity and directly inhibiting viral replication. Understanding IFN-HBV interactions aids developing new curative therapies for this global health challenge.

Keywords:

HBV HBV drug ISGs TRIMs cccDNA interferon

More Related Videos

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Related Experiment Videos

Last Updated: Feb 7, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Area of Science:

Hepatology
Virology
Immunology

Background:

Chronic hepatitis B virus (HBV) infection is a major global health concern with millions lacking curative treatments.
Interferon (IFN), including pegylated IFN, is an approved therapy that offers direct antiviral effects and enhances anti-HBV immunity.

Purpose of the Study:

To systematically review and summarize recent research on the complex interactions between Interferon (IFN) and the hepatitis B virus (HBV).
To dissect the specific antiviral mechanisms employed by IFN against HBV infection.
To discuss current IFN-based treatment strategies and future therapeutic development.

Main Methods:

Systematic literature review of research on IFN-HBV interactions.
Analysis of IFN's antiviral mechanisms, including IFN-stimulated genes (ISGs).
Examination of HBV's counter-mechanisms against IFN signaling.

Main Results:

IFN inhibits HBV replication through IFN-stimulated genes (ISGs).
HBV and its viral proteins can inhibit IFN signaling pathways.
A complex interplay exists between IFN and HBV, influencing treatment efficacy.

Conclusions:

Understanding the intricate crosstalk between IFN and HBV is crucial for improving current therapies.
Further research into IFN's mechanisms and HBV's evasion strategies will facilitate the development of novel direct-acting and immunotherapy-based drugs for chronic HBV.
This review provides insights to advance the development of curative HBV treatments.